Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable …

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - journals.lww.com
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
被引用次数：179 相关文章

[引用][C] Surgical Outcome Results From SWOG S1505

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - cir.nii.ac.jp

Surgical Outcome Results from SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - profiles.wustl.edu
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - europepmc.org
Objective The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - journals.lww.com
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
[HTML] nih.gov

[HTML][HTML] Surgical Outcome Results from SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - ncbi.nlm.nih.gov
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal… - Annals of …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Surgical Outcome Results from SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal… - Annals of …, 2020 - scholars.northwestern.edu
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Surgical Outcome Results from SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of …

SA Ahmad, M Duong, DPS Sohal… - Annals of …, 2020 - utsouthwestern.elsevierpure.com
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …